Azenta Förvaltning
Förvaltning kriterier kontrolleras 1/4
Azenta VD är John P. Marotta, utsedd i Sep 2024, har en mandatperiod på 1.58 år. totala årliga ersättningen är $ 10.37M, bestående av 8.7% lön 91.3% bonusar, inklusive företagsaktier och optioner. äger direkt 0.083% av företagets aktier, värda $ 880.56K. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 1.6 år respektive 2.3 år.
Viktig information
John P. Marotta
Verkställande direktör
US$10.4m
Total ersättning
| VD-lön i procent | 8.68% |
| Anställning som VD | 1.6yrs |
| Ägande av VD | 0.08% |
| Ledningens genomsnittliga anställningstid | 1.6yrs |
| Styrelsens genomsnittliga mandatperiod | 2.3yrs |
Senaste uppdateringar av ledningen
Recent updates
AZTA: 2026 Guidance And Space Research Will Support Sentiment Recovery
Azenta's analyst price target has been trimmed by about $2.50 as analysts factor in updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E following a series of recent target cuts from major firms. Analyst Commentary Recent Street research on Azenta points to a more cautious tone on valuation, with multiple price target trims clustering over a relatively short period.AZTA: 2026 Guidance And Space Research Tests Will Support Sentiment Recovery
Azenta's analyst price targets have been reduced by $5 to $9 in recent updates, as analysts factor in revised expectations for the diagnostic tools group and place greater emphasis on 2026 guidance and the clarity of the company's multi year growth framework. Analyst Commentary Recent research updates on Azenta show a mix of optimism around the long term framework and caution around the nearer term setup, with price targets adjusted both higher and lower as estimates and expectations are refreshed.Azenta: Life Science Player Fails To Come To Life
Mar 24AZTA: 2026 Guidance And Space Research Partnership Will Support Sentiment Recovery
Azenta's analyst price targets have edged lower by a mid single digit dollar amount to around $39, as analysts factor in updated discount rate and growth assumptions, while still highlighting the importance of 2026 guidance and multi year frameworks for potential upside. Analyst Commentary Bullish Takeaways Bullish analysts point to the move to a US$39 price target as a reflection of clearer multi year planning, which supports their view that the company has several paths to grow into that valuation over time.AZTA: 2026 Framework And Buybacks Will Underpin Sentiment Recovery
Narrative Update: Azenta Azenta's latest analyst price targets have shifted slightly lower in recent research updates, with firms trimming their views by $5 and $9 after a prior increase to $39, as analysts factor in group wide adjustments in diagnostic tools and place more weight on visibility into the company's multi year framework and 2026 guidance. Analyst Commentary Recent research updates on Azenta reflect a mix of optimism about the long term setup and caution around execution and visibility, especially as analysts refresh their views on the broader diagnostic tools group and Azenta's multi year framework.
Automation And Biorepositories Will Steadily Support A Fairly Valued Long Term Outlook
Catalysts About Azenta Azenta provides life sciences customers with sample management, biorepositories and multiomics services such as next-generation sequencing and gene synthesis. What are the underlying business or industry changes driving this perspective?AZTA: 2026 Margin Framework And Buybacks Will Support Future Upside
Analysts have trimmed their average price target on Azenta from about $43.50 to roughly $38.67, reflecting recent target cuts of $5 and $9, along with updated views on revenue growth, margins and a lower future P/E assumption. Analyst Commentary Recent research shows a mixed but detailed set of views around Azenta, with some focusing on long term growth potential and others dialing back expectations on valuation and near term execution.
Multiomics Outsourcing And Automation Will Drive A Powerful Long Term Earnings Shift
Catalysts About Azenta Azenta provides life sciences customers with sample management, multiomics services and automation solutions across biorepositories, sequencing and gene synthesis. What are the underlying business or industry changes driving this perspective?AZTA: 2026 Margin Path And Buybacks Will Support Upside Potential
Analysts have nudged up their Azenta targets, with one moving to US$39 and another to US$45. This reflects interest in the company’s multi year growth framework and expectations for mid single digit organic revenue trends, with a path to margins above 20%.AZTA: Biopharma Exposure And 2026 Margin Path Support Balanced Risk Reward
Analysts have lifted their price target on Azenta to about US$43.50 from roughly US$40.17, citing slightly lower revenue growth expectations, firmer profit margin assumptions and a modestly lower future P/E outlook. The revised target is supported by recent research that notes improving sentiment, mid single digit organic revenue ambitions and a path to higher margins into 2026.AZTA: Biopharma Exposure Will Support Margin Expansion And 2026 Re Rating Potential
Analysts have nudged their fair value estimate for Azenta slightly higher to about $40, reflecting updated price targets in the mid to high $30s and low $40s, and their view that organic revenue growth and margin expansion potential into 2026 support a more constructive outlook on the shares. Analyst Commentary Recent research updates highlight a more constructive tone on Azenta, with several firms lifting price targets and turning more positive after the latest fiscal Q4 report and ahead of the upcoming investor day.AZTA: Biopharma Exposure Will Support Mid-Single-Digit Growth And Margin Expansion
Azenta's analyst price target has been raised by $10 to $45, as analysts point to mid single digit plus organic revenue growth prospects and a credible path to margins above 20% that is supported by healthy biopharma exposure and multiple growth drivers into 2026. Analyst Commentary Bullish analysts highlight that the latest results, while largely in line with expectations, reinforce confidence in Azenta's ability to sustain mid single digit plus organic revenue growth while steadily expanding margins above 20% over the medium term.AZTA: Mid-Single-Digit Organic Revenue Acceleration Will Broaden Profit Margins Into 2026
Azenta's analyst price target has increased from $35.17 to $39.83. Analysts cite in-line financial results and ongoing optimism around revenue growth and expanding profit margins, supported by sector exposure and long-term innovation opportunities.Azenta's (NASDAQ:AZTA) Earnings Offer More Than Meets The Eye
Nov 28
AZTA: Growth Drivers From Biopharma Exposure And Acquisitions Will Unlock Opportunity
Analysts have raised their price target for Azenta from $30 to $38, citing expectations for increased growth opportunities and a positive outlook. This outlook is based on innovation, robust biopharma exposure, and prospective acquisitions.AZTA: Biopharma Demand and Acquisition Focus Will Drive Shares Higher Through 2026
Azenta's analyst price target has been raised from $33 to approximately $35.17 per share. Analysts cite increased confidence in the company's growth drivers and mid-term opportunities, particularly within the biopharma sector.Is There Now An Opportunity In Azenta, Inc. (NASDAQ:AZTA)?
Sep 12Azenta, Inc. (NASDAQ:AZTA) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Aug 07Calculating The Fair Value Of Azenta, Inc. (NASDAQ:AZTA)
Jul 24Pharma And Biotech Outsourcing Will Shape Future Market Dynamics
Strong industry trends and Azenta's infrastructure investments are driving above-market growth, recurring revenues, and operating leverage in sample management and biobanking.Azenta: Life Science Business Failing To Come To Life
Apr 17Azenta, Inc.'s (NASDAQ:AZTA) 29% Share Price Plunge Could Signal Some Risk
Apr 05Are Investors Undervaluing Azenta, Inc. (NASDAQ:AZTA) By 50%?
Mar 28Azenta: Taking A Pass
Jan 27At US$51.81, Is Azenta, Inc. (NASDAQ:AZTA) Worth Looking At Closely?
Jan 10A Look At The Intrinsic Value Of Azenta, Inc. (NASDAQ:AZTA)
Dec 20Analysts Have Just Cut Their Azenta, Inc. (NASDAQ:AZTA) Revenue Estimates By 14%
Nov 17Shareholders Should Be Pleased With Azenta, Inc.'s (NASDAQ:AZTA) Price
Nov 14Azenta: Life Science Play Is Not Coming To Life
Sep 11Azenta, Inc.'s (NASDAQ:AZTA) Shares May Have Run Too Fast Too Soon
Jul 19Should You Investigate Azenta, Inc. (NASDAQ:AZTA) At US$52.18?
Apr 27Shareholders Should Be Pleased With Azenta, Inc.'s (NASDAQ:AZTA) Price
Apr 05Analys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | US$26m |
| Sep 30 2025 | US$10m | US$900k | US$24m |
| Jun 30 2025 | n/a | n/a | -US$25m |
| Mar 31 2025 | n/a | n/a | -US$26m |
| Dec 31 2024 | n/a | n/a | -US$24m |
| Sep 30 2024 | US$1m | US$35k | -US$24m |
Ersättning vs marknad: John P. s total kompensation ($USD 10.37M ) är över genomsnittet för företag av liknande storlek på US marknaden ($USD 3.70M ).
Ersättning vs inkomst: Ersättningen från John P. har varit i linje med företagets resultat under det senaste året.
VD OCH KONCERNCHEF
John P. Marotta (44 yo)
1.6yrs
Anställning
US$10,371,415
Kompensation
Mr. John P. Marotta is President, CEO & Director of Azenta, Inc. from September 9, 2024. He joined the Azenta, Inc. on September 9, 2024. He is Chief Executive of EMERGE Medical Inc. He is Member of Adviso...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| President | 1.6yrs | US$10.37m | 0.083% $ 880.6k | |
| Executive VP & CFO | 1.4yrs | US$3.91m | 0.054% $ 571.9k | |
| Senior VP | less than a year | US$2.80m | inga uppgifter | |
| Senior VP & Chief HR Officer | 2.7yrs | US$1.70m | 0.012% $ 127.7k | |
| Advisor | 6.9yrs | US$1.55m | 0.027% $ 290.3k | |
| VP, Chief Information & Digital Officer | 8.8yrs | inga uppgifter | inga uppgifter | |
| Vice President of Financial Planning & Analysis and Investor Relations | no data | inga uppgifter | inga uppgifter | |
| President of Multiomics Business | no data | inga uppgifter | inga uppgifter | |
| Strategic Technical Specialist of Azenta Life Sciences | no data | inga uppgifter | inga uppgifter | |
| Vice President and General Manager of Sample Repository Solutions | no data | inga uppgifter | inga uppgifter |
1.6yrs
Genomsnittlig anställningstid
48.5yo
Genomsnittlig ålder
Erfaren ledning: AZTA s ledningsgrupp anses inte vara erfaren ( 1.6 års genomsnittlig anställningstid), vilket föreslår ett nytt team.
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| President | 1.6yrs | US$10.37m | 0.083% $ 880.6k | |
| Independent Director | 3.3yrs | US$293.25k | 0.034% $ 364.8k | |
| Independent Director | 2.3yrs | US$295.12k | 0% $ 0 | |
| Independent Vice Chair of the Board | 12.8yrs | US$303.19k | 0.088% $ 939.9k | |
| Independent Director | 1.4yrs | US$288.87k | 0.059% $ 625.5k | |
| Independent Director | 6yrs | US$301.37k | 0.049% $ 520.9k | |
| Independent Director | 1.3yrs | US$267.62k | 0.021% $ 224.5k | |
| Independent Chairman | 4.4yrs | US$404.77k | 0.047% $ 504.3k | |
| Independent Director | 1.4yrs | US$289.50k | 0.011% $ 116.4k |
2.3yrs
Genomsnittlig anställningstid
61yo
Genomsnittlig ålder
Erfaren styrelse: AZTA s styrelse anses inte vara erfaren ( 2.3 års genomsnittlig mandatperiod), vilket föreslår en ny styrelse.
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/04/30 01:43 |
| Aktiekurs vid dagens slut | 2026/04/30 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/09/30 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Azenta, Inc. bevakas av 15 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Christopher Muse | Barclays |
| Brett Hodess | BofA Global Research |
| Paul Knight | Brean Capital Historical (Janney Montgomery) |